Overview
Theranos promised to make blood testing easier through small fingerstick samples and compact testing equipment. Elizabeth Holmes founded the company in 2003. It attracted major retail relationships and substantial investment before its claims, laboratory practices, and financial representations faced scrutiny.[1][4]
The company announced plans to wind down in September 2018 after efforts to find a buyer failed. Later criminal trials established fraud, while subsequent proceedings continued after the operating venture ended. The central lesson concerns the gap between a persuasive medical claim and independently checkable evidence that supports its exact scope.[9][3]
Image 1 / 1
Photo license: CC BY 2.0.
Founding Story
Holmes founded Theranos in 2003 and remained chief executive until 2018. The later appellate record describes a goal of performing laboratory tests on small samples collected from a fingerstick. Ramesh “Sunny” Balwani joined in 2009 and became president and chief operating officer. He was not a co-founder.[4]
The proposition addressed a familiar discomfort: blood draws and laboratory visits could be unpleasant, slow, or inconvenient. Reducing the sample and simplifying access would offer real value if the necessary tests remained accurate and clinically useful. The desired customer experience did not establish that the proposed device could deliver it.
In a 2014 CNN interview, Holmes described “test by test redeveloping the chemistry.” Asked about review, she said, “We're certified as a high-complexity lab.” These were historical claims. Laboratory certification did not establish that every advertised assay performed as promised.[14]
Theranos combined chemistry, hardware, software, sample collection, laboratory operations, and distribution. The broad promise required evidence across those parts. A successful demonstration of one narrow assay could not establish a complete testing menu.
Timeline
- 2003: Holmes founded Theranos.[4]
- 2009: Balwani joined the company.[4]
- 2015: FDA reviewed a specific Theranos HSV-1 antibody assay and associated sample-collection system.[6]
- June 12, 2016: Walgreens announced immediate termination and closure of forty Arizona Theranos centers.[7]
- April 2017: Arizona announced a consumer restitution settlement; eligible consumers received payments that December.[8]
- March 2018: SEC brought civil fraud charges and announced the company and Holmes's settlement.[1]
- September 2018: The company announced its planned wind-down.[9]
- January 2022: A jury convicted Holmes on investor-related counts and acquitted her on patient-related counts.[3]
- March 26, 2026: A district court order reduced her prison sentence to 123 months.[5]
What They Built
Theranos developed proprietary collection containers and testing equipment, including the Edison. The appellate opinion distinguishes the Edison, used on patient samples, from other devices still under development. That distinction matters when assessing which product a demonstration or later presentation actually showed.[4]
The SEC complaint alleged that Theranos's own analyzer handled only about twelve tests from a menu exceeding two hundred, while conventional equipment performed much of the rest. The problem was therefore more specific than a device that performed no testing at all: public and investor representations exceeded the demonstrated capability of the proprietary system.[2]
FDA's decision summary for the HSV-1 IgG assay also prevents an overbroad account. It describes one antibody assay, specified specimens, and associated collection devices. It does not establish broad clearance for every claimed Theranos test. Equally, the record does not support saying that no Theranos product ever received FDA clearance.[6]
Market Position
Target Customers
Patients were promised easier access to testing. Retail partners could bring collection closer to where people already shopped. The Walgreens network supplied a visible route to customers, but its presence did not independently validate every technical claim. Walgreens's eventual withdrawal removed a concrete distribution channel.[7]
Market Size
The reviewed record does not establish a defensible addressable market for Theranos's claimed system. Total laboratory spending includes many tests and settings beyond the capability of one compact analyzer. Counting that spending would obscure the need to prove particular tests, users, and workflows.
Competition
Established laboratories and conventional analyzers were both alternatives and, according to the trial record, part of Theranos's actual testing process. The competitive claim depended on superior capability and convenience from proprietary equipment. Using standard machines without accurately disclosing their role undermined that claim.[3]
Business Model
The company sought revenue from testing and commercial relationships, while raising private capital to develop the platform. SEC's March 2018 announcement described more than $700 million raised through the alleged scheme. That is a regulator's scoped financing claim, without establishing a single audited lifetime total or the amount ultimately returned.[1]
The detailed complaint also alleged a large difference between financial representations and actual sales. It described 2014 revenue claims exceeding $100 million against recorded revenue only a little above $100,000. These figures are allegations in the civil complaint, rather than independently reconstructed financial statements in this review.[2]
Medical validation, commercial demand, and truthful fundraising were separate requirements. A plausible need for better testing could not excuse misleading investors or patients while the technology was still being developed.
Outcome and evolution
The 2018 civil settlement did not include an admission or denial of the SEC allegations. The later criminal verdict supplied a different evidentiary result. Holmes was convicted of investor conspiracy and three investor wire-fraud counts; the jury acquitted her on patient-related counts and did not reach verdicts on three other investor counts.[1][3]
The December 2025 amended appellate opinion upheld the convictions, sentences, and restitution order then under review. A later March 2026 district court order changed Holmes's sentence from the original 135 months to 123 months under revised sentencing rules. That modification did not erase the conviction. A sentence term also differs from an estimated release or transfer date.[4][5]
The consumer and company outcomes require their own scope. Arizona's current page says the $4.65 million consumer restitution settlement is closed and payments were distributed. The September 2018 shutdown report describes a failed sale effort and planned creditor process. It does not establish that every creditor or shareholder received a recovery.[8][9]
The alternative explanation of ambitious science failing under commercial pressure is insufficient for this case. Technical failure can happen without fraud. The trial record establishes knowing false representations as well as product limitations. Avoiding deception required accurate disclosure even if further development remained possible.[3]
This review did not verify a complete successor service, every intellectual-property transfer, or a precise legal dissolution filing date. The Department of Justice describes the original company as defunct.[3]
Key Lessons
- Match each medical claim to evidence for the exact test, specimen, configuration, and intended use.
- Keep an investor presentation consistent with the actual product and financial record.
- Preserve independent technical challenge even when a partnership or prominent backer creates confidence.
- Distinguish allegations, settlements, verdicts, appeals, and later sentence changes.
Sources
- SEC civil charges and settlement
- SEC detailed complaint
- DOJ Holmes trial and original sentence account
- Ninth Circuit amended opinion
- 2026 sentence modification order
- FDA HSV1 assay review
- Walgreens partnership termination
- Arizona consumer restitution status
- September2018 shutdown plan report
- 2014 documentary portrait provenance
- Holmes CNN interview transcript — October 18, 2014.